Exploring the Connection Between Diabetes Medication and Dementia Risk
Wednesday, 18 September 2024, 13:00
Overview of the Study
A specific type of diabetes medication has been associated with a lower risk of dementia, Alzheimer's, and Parkinson's disease in a study published today. The South Korean study followed 358,862 participants with type 2 diabetes and found that those taking sodium-glucose cotransporter-2 (SGLT2) inhibitors had a 22 percent lower risk of developing dementia or Parkinson's compared with type 2 diabetics taking different medications.
Key Findings
- SGLT2 inhibitors may be effective in reducing the risk of neurodegenerative diseases.
- Risk reduction applies to dementia, Alzheimer's disease, and Parkinson's disease.
- The research highlights a potential new avenue in treating patients with diabetes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.